1. Predicting Hospital Rates of Fluoroquinolone-Resistant Pseudomonas aeruginosa from Fluoroquinolone Use in US Hospitals and Their Surrounding Communities
- Author
-
Ron E. Polk, Donna K. McClish, Michael B. Edmond, Christopher K. Johnson, and Richard P. Wenzel
- Subjects
Adult ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,Microbial Sensitivity Tests ,medicine.disease_cause ,Predictive Value of Tests ,Levofloxacin ,Internal medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Infection control ,Pseudomonas Infections ,Medical prescription ,Intensive care medicine ,Antibacterial agent ,Cross Infection ,Infection Control ,business.industry ,Pseudomonas aeruginosa ,Length of Stay ,Middle Aged ,Quinolone ,United States ,Fluoroquinolone resistance ,Anti-Bacterial Agents ,Community-Acquired Infections ,Ciprofloxacin ,Infectious Diseases ,Population Surveillance ,Communicable Disease Control ,Female ,business ,Fluoroquinolones ,medicine.drug - Abstract
Rates of fluoroquinolone resistance among Pseudomonas aeruginosa in hospitals are increasing, but interhospital variability is great. We sought to determine whether this variability correlated to fluoroquinolone use in hospitals and in the surrounding community. Hospital quinolone use in 1999 (24 hospitals) through 2001 (35 hospitals) was determined from billing records. The number of fluoroquinolone prescriptions within a 10-mile (approximately 16-km) radius of each hospital was determined for 1999 and 2000. Hospital fluoroquinolone use increased from 1999 through 2001, from 137 to 163 defined daily doses (DDD)/1000 patient-days (P=.01). The rate of community fluoroquinolone use also increased, from 2.3 to 2.8 DDD/1000 inhabitant-days (P
- Published
- 2004
- Full Text
- View/download PDF